DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Show more
Location: 301 Carlson Parkway, Minneapolis, MN, 55305, United States | Website: https://www.diamedica.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
274M
52 Wk Range
$3.19 - $6.82
Previous Close
$5.30
Open
$5.29
Volume
530,054
Day Range
$5.15 - $5.76
Enterprise Value
244.2M
Cash
30.04M
Avg Qtr Burn
-6.413M
Insider Ownership
31.58%
Institutional Own.
37.37%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
DM199 (KLK1 protein) Details Heart disease, Ischemic stroke | Phase 2/3 Data readout | |
DM199 (KLK1 protein) Details Preeclampsia | Phase 2 Data readout | |
DM199 (KLK1 protein) Details Chronic inflammatory disorder, Inflammatory disease, Kidney disease, IgA nephropathy, Chronic kidney disease | Phase 2 Update |